FDA Warns Against Power Morcellators

There has been much written about the relationship between power morcellators for fibroid surgery and onset of disseminated cancer. Though the debate goes on, Andrew Kaunitz, editor in chief of the New England Journal of Medicine, Journal Watch Women’s Health, commented, “Today’s FDA’s announcement use of morcellators as a part of minimally invasive hysterectomy or myomectomy for women with symptomatic uterine fibroids will essentially cease as most women with symptomatic fibroids will fill at least one of the contraindication criteria.”

All articles in this blog are the collaborative effort of attorneys Jerry Meyers, Brendan Lupetin, and Gregory Unatin.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

What are you looking for?

During these unusual circumstances concerning the coronavirus, we are working to respond as quickly as possible to your phone calls and emails. You can expect to hear back from us within 24 hours or one business day (Monday – Friday).